Comparative Study on Postoperative Treatments for Gastric Cancer

Overview of Gastric Carcinoma

Gastric carcinoma, a cancer that arises in the stomach lining, is a relatively rare form of cancer but is responsible for over 2,000 deaths annually in Canada, as reported by the Canadian Cancer Society. The five-year survival rate for this type of cancer is only 25%, which has spurred extensive research efforts aimed at discovering optimal treatment strategies to enhance patient outcomes.

Treatment Approaches for Gastric Cancer

Treatment for gastric cancer typically involves a multifaceted approach, which may include chemotherapy, radiation, and surgery, depending on the cancer stage. In certain cases, preoperative chemotherapy is administered to reduce tumor size, facilitating a more effective surgical removal. Following surgery, patients may receive postoperative chemotherapy or chemoradiotherapy to eliminate any remaining tumor cells and reduce the risk of recurrence.

Phase-3 Clinical Trial Findings

A recent phase-3 clinical trial published in the journal Lancet Oncology examined the effectiveness of postoperative chemotherapy compared to chemoradiotherapy in patients who had undergone surgical resection combined with preoperative chemotherapy. The study aimed to evaluate “perioperative chemotherapy” (administered just before and after surgery) against “postoperative chemoradiotherapy” (involving chemotherapy and radiation after surgery).

Study Design and Patient Demographics

Conducted by independent researchers, the open-label study involved 788 patients from 56 institutions across the Netherlands, Denmark, and Sweden. The trial tracked participants from January 11, 2007, to April 17, 2015. Patients were randomly assigned to either the chemotherapy (393 patients) or chemoradiotherapy (395 patients) group, with treatments commencing 4 to 12 weeks after surgery.

Results and Survival Rates

Patients were categorized based on tumor characteristics, including histological subtype and localization. Despite the rigorous treatment, a significant number of patients faced disease progression post-surgery, with only about 233 in the chemotherapy group and 245 in the chemoradiotherapy group receiving their respective postoperative regimens. The survival rates between the two groups did not show significant differences, with overall survival at approximately 37 months for chemoradiotherapy and 43 months for chemotherapy.

Adverse Events and Treatment Tolerability

To assess treatment tolerability, the study documented adverse events categorized by severity. Approximately 48% of patients in the chemotherapy group experienced grade 3 or 4 adverse events, compared to 41% in the chemoradiotherapy group. The findings indicated that the tolerability of both postoperative regimens was relatively similar following initial surgical intervention.

Conclusions

The study concluded that the effectiveness of perioperative chemotherapy does not significantly differ from that of postoperative chemoradiotherapy after surgical resection and preoperative chemotherapy. These results suggest that future research and clinical efforts should prioritize enhancing the effectiveness of preoperative chemotherapy rather than focusing on the differentiation of postoperative treatment approaches.

Reference

Cats, A., Jansen, E. P. M., van Grieken, N. C. T., Sikorska, K., Lind, P., Nordsmark, M., . . . investigators, C. (2018). Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol, 19(5), 616-628. doi:10.1016/S1470-2045(18)30132-3